Precipio, Inc. - Common Stock (PRPO)
Competitors to Precipio, Inc. - Common Stock (PRPO)
Cancer Genetics, Inc.
Cancer Genetics, Inc. provides a range of genomic and biomarker tests specifically designed for oncology. Their portfolio includes diagnostic tests that help in cancer prediction and monitoring, and they also engage in drug development partnerships. While they compete directly with Precipio by targeting similar market segments, Cancer Genetics has established a strong focus on developing specific tests for targeted therapies, giving them an advantage in niche markets compared to Precipio's broader service offering.
Genetic Technologies Limited
Genetic Technologies Limited focuses on developing and commercializing innovative medical diagnostic tests, particularly in the field of genomics. Like Precipio, they target the oncology and personalized medicine markets, offering services that include risk assessment and genetic testing. Both companies aim to improve patient outcomes through advanced diagnostic methods. However, Genetic Technologies has made significant strides in establishing partnerships and gaining market access in Australia and the US, giving them an edge in brand recognition and customer trust. This improves their competitive positioning.
Guardant Health, Inc. GH -6.47%
Guardant Health is a biotechnology company focused on blood-based cancer testing. They compete with Precipio in the liquid biopsy market, offering a range of tests that analyze circulating tumor DNA to detect, monitor, and potentially guide treatment for cancer patients. Guardant Health's advanced technology and significant investment in research and development provide them with a notable edge in innovation and accuracy, positioning them as a leader in this specific niche of the oncology market.
Myriad Genetics, Inc. MYGN -1.03%
Myriad Genetics, Inc. is a leader in the molecular diagnostics sector, specializing in hereditary cancer tests, as well as other genetic testing services. They compete with Precipio by providing advanced testing solutions that identify genetic predispositions for various cancers, thus allowing for personalized treatment plans. Myriad's established reputation and extensive market presence provide them with a competitive advantage over Precipio, especially in terms of customer relationships and comprehensive service offerings.
Trovagene, Inc.
Trovagene, Inc. specializes in cell-free DNA testing for cancer detection and monitoring, similar to Precipio's services. They offer a range of diagnostic products that serve to enhance cancer care, making them a direct competitor in the oncology diagnostics arena. However, Trovagene has faced fluctuations in their operational success and market perception, which may hinder their competitive effectiveness relative to Precipio’s focus on strategic partnerships and operational stability at this time.